Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study

被引:26
作者
Schroeder, H. [1 ]
Wacher, J. [1 ]
Larsson, H. [2 ]
Rosthoej, S. [3 ]
Rechnitzer, C. [4 ]
Pedersen, B. L. [5 ]
Carlsen, N. L. T. [6 ]
机构
[1] Aarhus Univ Hosp, Dept Pediat, DK-8200 Aarhus, Denmark
[2] Univ Aarhus, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark
[3] Univ Hosp Aalborg, Dept Pediat, DK-9000 Aalborg, Denmark
[4] Natl State Hosp Denmark, Juliane Marie Ctr, Dept Pediat, DK-2100 Copenhagen, Denmark
[5] Natl State Hosp Denmark, Dept Pathol, DK-2100 Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Pediat, DK-5000 Odense, Denmark
关键词
neuroblastoma; incidence; population-based; survival; mortality; STAGE-4; NEUROBLASTOMA; PROGNOSTIC-FACTORS; DISEASE; EUROPE; NORTH; AGE;
D O I
10.1038/sj.bjc.6604922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment results for neuroblastoma in Denmark have been poorer than in other Nordic countries, so we investigated whether a change in incidence, stage distribution and survival had occurred between 1981 and 2000. Clinical data were retrieved from the medical charts of 160 children <15 years of age with extra-cranial neuroblastoma (n = 139) or ganglioneuroblastoma (n = 21) diagnosed in Denmark between 1981 and 2000. The minimal follow-up time was 52 months. Statistical analyses were performed in STATA. The incidence was 8.55 per million children below 15 years of age (world standard 9.6) and 42.6 per million children below 12 months of age, and it has remained unchanged since 1970. The median age at diagnosis was 27 months. In all, 32% of the children were aged below 12 months at diagnosis, 53% had metastatic disease and in 12% the diagnosis was made incidentally. Prognostic factors such as age, stage and site of primary tumour were the same as in other studies and did not change. During the study period, the mortality rate decreased steadily, and the 5-year survival rate increased from 38% in 1981 - 1985 to 59% in 1996 - 2000, corresponding to the level found in other Western countries. Increased survival was also seen in children with metastatic disease. Participation in international studies, better supportive care and possibly postoperative autologous stem cell transplantation may have contributed to the increased survival.
引用
收藏
页码:853 / 857
页数:5
相关论文
共 20 条
[1]   A POPULATION-BASED STUDY OF NEUROBLASTOMA INCIDENCE, SURVIVAL, AND MORTALITY IN NORTH-AMERICA [J].
BERNSTEIN, ML ;
LECLERC, JM ;
BUNIN, G ;
BRISSON, L ;
ROBISON, L ;
SHUSTER, J ;
BYRNE, T ;
GREGORY, D ;
HILL, G ;
DOUGHERTY, G ;
SCRIVER, C ;
LEMIEUX, B ;
TUCHMAN, M ;
WOODS, WG .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :323-329
[2]   Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age [J].
Berthold, F ;
Hero, B ;
Kremens, B ;
Handgretinger, R ;
Henze, G ;
Schilling, FH ;
Schrappe, M ;
Simon, T ;
Spix, C .
CANCER LETTERS, 2003, 197 (1-2) :11-17
[3]  
Brodeur G M, 1994, Prog Clin Biol Res, V385, P363
[4]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[5]  
Carlsen N L, 1994, Acta Paediatr Suppl, V403, P1
[6]   EPIDEMIOLOGIC INVESTIGATIONS ON NEUROBLASTOMAS IN DENMARK 1943-1980 [J].
CARLSEN, NLT .
BRITISH JOURNAL OF CANCER, 1986, 54 (06) :977-988
[7]  
CARLSEN NLT, 1986, CANCER-AM CANCER SOC, V58, P2726, DOI 10.1002/1097-0142(19861215)58:12<2726::AID-CNCR2820581229>3.0.CO
[8]  
2-M
[9]   HOW FREQUENT IS SPONTANEOUS REMISSION OF NEUROBLASTOMAS - IMPLICATIONS FOR SCREENING [J].
CARLSEN, NLT .
BRITISH JOURNAL OF CANCER, 1990, 61 (03) :441-446
[10]  
Cotterill SJ, 2001, MED PEDIATR ONCOL, V36, P231, DOI 10.1002/1096-911X(20010101)36:1<231::AID-MPO1056>3.0.CO